P
Peter F. Wright
Researcher at Dartmouth–Hitchcock Medical Center
Publications - 75
Citations - 6229
Peter F. Wright is an academic researcher from Dartmouth–Hitchcock Medical Center. The author has contributed to research in topics: Vaccination & Antibody. The author has an hindex of 27, co-authored 66 publications receiving 5303 citations. Previous affiliations of Peter F. Wright include Northwestern University & Vanderbilt University Medical Center.
Papers
More filters
Journal ArticleDOI
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
Harish Nair,Harish Nair,D. James Nokes,D. James Nokes,Bradford D. Gessner,Mukesh Dherani,Shabir A. Madhi,Rosalyn J. Singleton,Katherine L. O'Brien,Anna Roca,Anna Roca,Peter F. Wright,Nigel Bruce,Aruna Chandran,Evropi Theodoratou,Agustinus Sutanto,Endang R. Sedyaningsih,Mwanajuma Ngama,Patrick K. Munywoki,Cissy B. Kartasasmita,Eric A. F. Simões,Igor Rudan,Igor Rudan,Martin Weber,Harry Campbell +24 more
TL;DR: Mortality data suggest that RSV is an important cause of death in childhood from ALRI, after pneumococcal pneumonia and Haemophilus influenzae type b, and the development of novel prevention and treatment strategies should be accelerated as a priority.
Journal ArticleDOI
Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis
Harish Nair,Harish Nair,W. Abdullah Brooks,Mark A. Katz,Anna Roca,James A. Berkley,Shabir A. Madhi,James Mark Simmerman,Aubree Gordon,Aubree Gordon,Masatoki Sato,Stephen R. C. Howie,Anand Krishnan,Maurice Ope,Kim A. Lindblade,Phyllis Carosone-Link,Marilla G. Lucero,Walter Onalo Ochieng,Laurie Kamimoto,Erica Dueger,Niranjan Bhat,Sirenda Vong,Evropi Theodoratou,Malinee Chittaganpitch,Osaretin Chimah,Osaretin Chimah,Angel Balmaseda,Philippe Buchy,Eva Harris,Valerie Evans,Masahiko Katayose,Bharti Gaur,Cristina O'Callaghan-Gordo,Doli Goswami,Wences Arvelo,Marietjie Venter,Thomas Briese,Rafal Tokarz,Marc-Alain Widdowson,Anthony W. Mounts,Robert F. Breiman,Daniel R. Feikin,Daniel R. Feikin,Keith P. Klugman,Keith P. Klugman,Sonja J. Olsen,Bradford D. Gessner,Peter F. Wright,Igor Rudan,Igor Rudan,Shobha Broor,Eric A. F. Simões,Harry Campbell +52 more
TL;DR: The role of influenza in childhood mortality from ALRI is estimated by combining incidence estimates with case fatality ratios from hospital-based reports and identifying studies with population-based data for influenza seasonality and monthly ALRI mortality.
Journal ArticleDOI
Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.
TL;DR: Although advances in molecular biology may ultimately lead to the development of more-immunogenic vaccine candidates, approaches such as increasing the number of doses of TOPV, mass vaccination campaigns, and combined use of oral and inactivated vaccines should also be considered.
Journal ArticleDOI
Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors
Morgan S.A. Gilman,Carlos A. Castellanos,Man Chen,Joan O. Ngwuta,Eileen C. Goodwin,Syed M. Moin,Vicente Mas,José A. Melero,Peter F. Wright,Barney S. Graham,Jason S. McLellan,Laura M. Walker +11 more
TL;DR: The human antibody response to the RSV fusion (F) glycoprotein is profile, finding that the response is broad but that more potent antibodies tend to target the apex of the prefusion conformation of RSV F, suggesting this site as a putative vaccine target.
Journal ArticleDOI
Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study
Marc Gurwith,Michael Lock,Eve M Taylor,Glenn Ishioka,Jeff Alexander,Tim Mayall,John E Ervin,Richard N. Greenberg,Cynthia Strout,John J. Treanor,Richard J. Webby,Peter F. Wright +11 more
TL;DR: The safety and immunogenicity of an oral adenovirus serotype 4 vector vaccine candidate expressing the haemagglutinin from an avian influenza A H5N1 virus was tested and no serious treatment-related adverse events occurred.